ABSI Rasio silihan jangka dawa marang modal absci.com

The price chart (separate_debt_long_eq) for Absci (ABSI) illustrates the performance of the company developing protein therapeutics via generative AI. The current metric stands at 0.01, driven by massive software development costs that are limiting profit growth. Despite its status as an innovator trusted by pharmaceutical industry leaders, the business faces liquidity shortages and the uncertainty associated with the early stages of its technology implementation.

Sean McClain's ambitions to create AI platforms in bioengineering require a balance between expansion and financial stability. The long-term debt-to-equity ratio, which stands at 0.01, reflects the proportion of liabilities with a maturity of more than one year to shareholders' equity, allowing investors to assess the leverage level and long-term debt risks associated with scaling innovations at Absci (ABSI).